Abstract
C1q is the first component of the classical complement pathway. Both clinically validated in-house ELISA assays as well as commercial ELISA kits are used for detection of anti-C1q antibodies. Anti-C1q autoantibodies can be detected in a wide range of autoimmune diseases and are highly sensitive for hypocomplementemic uticarial vasculitis. In SLE, anti-C1q are strongly associated with proliferative lupus nephritis, and their absence carries a negative predictive value for development of lupus nephritis of close to 100%. Anti-C1q in combination with anti-dsDNA and low complement has the strongest serological association with renal involvement. The anti-C1q titers correlate with global disease activity scores in patients with renal involvement, and higher titers seem to precede renal flares. After the successful treatment of a renal flare, anti-C1q has the tendency to decrease or even become undetectable. The main obstacle to the inclusion of anti-C1q in the classification criteria and clinical management of SLE is the lack of standardized laboratory assays.
Original language | English (US) |
---|---|
Pages (from-to) | 873-877 |
Number of pages | 5 |
Journal | Lupus |
Volume | 25 |
Issue number | 8 |
DOIs | |
State | Published - Jul 1 2016 |
Keywords
- C1q
- SLE
- Systemic lupus erythematosus
- anti-C1q
- lupus nephritis
ASJC Scopus subject areas
- Rheumatology